HeartBeam Q3 10-Q: $6.1M Cash, Going Concern Warning, Nasdaq Bid Deficiency
BEAT is trading near its 52-week low of $0.355 (12% above the low) on light trading volume (0.1× avg).
Summary
HeartBeam's Q3 10-Q carries a going-concern warning on $6.1 million of cash, discloses a Nasdaq minimum-bid deficiency with a December 28, 2026 deadline, and shows $4.0 million already raised under its ATM in Q4. The quarterly loss narrowed to $3.0 million from $5.3 million.
Key Events · Earnings and Guidance · BEAT
-
Going Concern Warning on $6.1M Cash
Management states that existing liquidity is insufficient to fund operations for the next twelve months following issuance of these financial statements; cash and equivalents stood at $6.1 million at September 30, 2026 versus $4.4 million at December 31, 2025.
-
Nasdaq Bid Deficiency, Deadline December 28
A June 30, 2026 Nasdaq deficiency letter flagged the closing bid below the $1.00 minimum under Rule 5550(a)(2); the 180-day compliance period runs to December 28, 2026, after which delisting or an additional compliance period is possible.
-
Q4 ATM Drawdown of $4.0M
Subsequent to quarter-end the company issued 5,799,795 shares under the ATM for approximately $4.0 million net proceeds, leaving about $21 million available under the $25 million sales agreement with Titan Partners.
-
Q3 Loss Narrows to $3.0M
Net loss was $3.0 million, or $(0.05) per share, versus $5.3 million, or $(0.15) per share, a year earlier; R&D fell 35% to $2.1 million and SG&A fell 33% to $1.3 million.
Analysis · BEAT · Industrial Applications And Services
HeartBeam ended September with $6.1 million in cash, and management states plainly that this is not enough to fund operations for the next twelve months — a going-concern warning that puts the burden on further equity sales. The company has already begun drawing on its $25 million ATM, issuing 5,799,795 shares for about $4.0 million in Q4, which leaves roughly $21 million available but keeps pressing on a share price already below $1.00. That price is the second problem: Nasdaq's June 30 deficiency letter gives the company until December 28, 2026 to regain the $1.00 minimum bid, and a reverse split or further dilution are the usual routes. The operating trend is at least moving the right way — the Q3 net loss narrowed to $3.0 million from $5.3 million a year earlier as R&D fell 35% and SG&A fell 33% — but with no product revenue and a pivotal heart-attack study planned for Q1 2027, the cash clock, not the expense line, sets the timetable.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BEAT was trading at $0.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $0.36 to $4.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.